DOLE-EUROPE/MY-ENERGY
With its "Dole Earth" program, Dole Europe has already shown consumers the broad commitment of its entire organisation to social engagement. This year the brand is again demonstrating its innovative side. Since mid-April it has been highlighting the significance of committing to a consistently healthy lifestyle for a long and fulfilling life – in a word, longevity – through its "My Energy" campaign. The key element of this consumer campaign is the specially developed "Energy Code" which crystallises the core aspects of longevity, i.e. a healthy diet, exercise and a genuinely heartfelt wish or goal. In all of its activities, the company attaches great importance to the intensive networking of its communication channels.
At the age of 92, Dole owner David H. Murdock is living proof of the fact that pursuing a passion is vital to those seeking to forge positive lives. The energetic entrepreneur has grand visions, particularly in the area of research. In 2005 he founded the North Carolina Research Campus (NCRC) – where the Dole Nutrition Institute is also located – which has already started producing unique work. Murdock is providing funds of $15 million per year to expand his vision of transforming the NCRC into the leading nutritional research centre in the USA and – in the long term – of exporting its expertise from Kannapolis to every corner of the globe. Murdock's own lifestyle is testament to how the Dole scientists' research can be put into practice. In his own charismatic way, the entrepreneur personifies the content of "My Energy" in line with the motto "Eat yourself healthy, exercise regularly and find a goal to pursue in life."
Expanded website with even greater thematic diversity
The place to start for interested consumers is the Dole website www.dole.eu which, with its "My Energy" section and an integrated blog, has simultaneously launched two new features. For the first aspect of the "My Energy" campaign, everything revolves around the three elements of the "Energy Code". Alongside emotional videos and portraits from within the company, Dole has included insights into the work of the Dole Nutrition Institute on the website. Interactivity is a key component of the program. German energy expert Ulrich Bauhofer developed an online test to help people optimise energy management in their everyday lives.
Beyond this, Dole’s comprehensive blogging portal – where guest authors are able to post their views – will be featuring additional detailed information throughout the campaign period. With changing focuses during the different phases, the brand will be offering new content on holistic lifestyles to its readers every week. The articles centre around the results of research conducted by Dole scientists, well-substantiated and proven background information on aspects of nutrition and exercise, and simple everyday tips for a healthier lifestyle. Throughout the year Dole will be supporting this, and all the other campaigns, with features on the brand's own Facebook page. As in its other communication channels, the emphasis here is on edutainment, i.e. a blend of education and entertainment.
Illustrating the spirit of this initiative, a truly special competition will be awaiting users at www.dole.eu . Dole is helping users fulfil their own personal wish by offering three raffle prizes of 4,000 euros. This promotion will also stimulate customer frequency in the stores and draw attention to the brand. Eye-catching red "My Energy" stickers on Dole bananas and tags on Dole pineapples will spark interest and – by displaying the URL – guide users towards the competition on the website.
From May onwards, Dole will be boosting its already powerful presence within the target group via a wide-ranging media partnership with the German online portal gofeminin.de. The site’s context and journalistic content will provide users with access to an array of ideas promoting dynamic lifestyles, and integrate direct links to Dole's digital channels.
About Dole Europe: Dole Europe is the European division of Dole Foods, one of the world's largest suppliers of fresh fruit and vegetables. Dole Europe imports a wide range of fresh produce from the Dole Food Company's own farms and plantations and from independent producers around the world. Dole Europe also creates innovative solutions for dealers in the realms of services and products. The company's network extends from Scandinavia to South Africa, from Italy to Russia and the Middle East. Further information is available at www.dole.eu .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150416006673/en/
Contact:
Dole Europe GmbH
Xavier Roussel
Stadtdeich 7, 20097 Hamburg,
Germany
xavier.roussel@dole.com
Tel.:
+49 40 32906-0
or
segmenta communications
Kristin Schuh
Feldbrunnenstrasse
52, 20148 Hamburg, Germany
schuh@segmenta.de
Tel.:
+49 40 44 11 30-44
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum